NOTICE:

In 2010, Optherion completed two separate business transactions, one related to its diagnostics business and one related to its therapeutics business.

With respect to its diagnostics business, in February, 2010, Optherion completed an exclusive worldwide licensing agreement with Sequenom, Inc.. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). Please see News Room at Optherion.com for Sequenom’s press release.

With respect to its therapeutics business, also in 2010, Optherion completed a business transaction with another company. Both the company name and the transaction economics are confidential.

As a result of these two transactions, Optherion, itself, is no longer actively developing any diagnostics or therapeutics. Given this, the Optherion.com website has not been updated since year-end, 2010 albeit the nature of Optherion’s diagnostic and therapeutic endeavors are accurately represented in the website for the time period prior to the transactions.

Kindest regards,

Colin J. Foster
President & CEO
Optherion, Inc.

Background, Epidemiology, and Natural History of AMD

The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited.
  • Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV.
  • Prog Retin Eye Res. 2010 Mar;29(2):95-112
Neovascular Age-Related Macular Degeneration and the Risk of Stroke. A 5-Year Population-Based Follow-Up Study.
  • Hu CC, Ho JD, Lin HC.
  • Stroke. 2010 Feb 11
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration.
  • Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL, Charbel Issa P, Scholl HP, Pollok-Kopp B, Schmid-Kubista KE, Bailey KR, Oppermann M.
  • Hum Mol Genet. 2010 Jan 1;19(1):209-15
Inflammation and the pathogenesis of age-related macular degeneration.
  • Augustin AJ, Kirchhof J.
  • Expert Opin Ther Targets. 2009 Jun; 13(6):641-51
Age-related macular degeneration: an immunologically driven disease.
  • Nussenblatt RB, Liu B, Li Z.
  • Curr Opin Investig Drugs. 2009 May;10(5):434-42
The spectrum of phenotypes caused by variants in the CFH gene.
  • Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI.
  • Mol Immunol. 2009 May;46(8-9):1573-94. Epub 2009 Mar 17. Review
Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.
  • Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J; Vision Health Cost-Effectiveness Study Group.
  • Arch Ophthalmol. 2009 Apr;127(4):533-40
The cost-effectiveness of treatment of age-related macular degeneration: a review.
  • Kymes Steven M.
  • Minerva Med. 2009 Feb;100(1):69-78
Systemic complement activation in age-related macular degeneration
  • Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Borncke F, Fritsche LG, Chong NV, Fimmers R, Wienker T, Holz FG, Weber BH, Oppermann M.
  • PLoS ONE, 2008 July 2;3(7):e2593
Age-related macular degeneration.
  • Jager RD, Mieler WF, Miller JW.
  • N Engl J Med. 2008 Jun 12;358(24):2606-17. Erratum in: N Engl J Med. 2008 Oct 16;359(16): 1736.
The role of complement in physiology and pathology
  • Centrum Biologtil Medycznej, Polska Akademia Nauk, Poland.
  • Postepy Hig Med Dosw (Online), 2007;61:167-77
Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H.
  • Bora NS, Kaliappan S, Jha P, Xu Q, Sohn JH, Dhaulakhandi DB, Kaplan HJ, Bora PS.
  • J Immunol. 2006 Aug 1;177(3):1872-8
Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.
  • Gehrs KM, Anderson DH, Johnson LV, Hageman GS.
  • Ann Med. 2006;38(7):450-71.
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.
  • Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R.
  • Proc Natl Acad Sci U S A. 2005 May 17;102(20):7053-4
The epidemiology of age-related macular degeneration
  • Seddon JM, Chen CA.
  • Int Ophthalmol Clin. 2004 Fall;44(4):17-39
Prevalence of age-related macular degeneration in the United States
  • Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group.
  • Arch Ophthalmol. 2004 Apr;122(4):564-72
The epidemiology of age-related macular degeneration
  • Klein R, Peto T, Bird A, Vannewkirk MR.
  • Am J Ophthalmol. 2004 Mar;137(3):486-95
The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study
  • van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT.
  • Arch Ophthalmol. 2003 Apr;121(4):519-26. Erratum in: Arch Ophthalmol. 2003 Jul;121(7):955.